The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
these are AV aocu app these are monoclonal antibodies to the pcsk9 protein which is involved in LDL receptor the only thing most listeners need to know here is that if you have a pcsk9 inhibitor you're going to have much much lower levels of LDL
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so the pcsk9 Inhibitors that we were talking about the evalacumab and olorakumab are monoclonal antibodies so pcsk9 is a hepatic Protein that's involved with LDL receptor degradation